Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ILF2-ASO
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
ILF2-ASO is an antisense oligonucleotide (ASO) designed with constrained ethyl (cEt) chemistry to target and deplete interleukin enhancer-binding factor 2 (ILF2). Developed through a collaboration between Ionis Pharmaceuticals and researchers at the University of Texas MD Anderson Cancer Center, ILF2-ASO is being investigated for the treatment of 1q21-amplified multiple myeloma (MM). ILF2 is an RNA-binding protein and a key modulator of the DNA repair pathway that is overexpressed in approximately 70% of patients with relapsed multiple myeloma, promoting tolerance to genomic instability and resistance to DNA-damaging agents. By depleting ILF2, ILF2-ASO induces DNA damage activation, inhibits cell proliferation, and sensitizes myeloma cells to genotoxic therapies such as melphalan, bortezomib, and olaparib.
- Other names
- ILF2 ASOILF-2 ASOILF 2 ASOILF2 antisense oligonucleotideILF-2 antisense oligonucleotideILF 2 antisense oligonucleotideILF2-targeting antisense oligonucleotideILF-2-targeting antisense oligonucleotideILF 2-targeting antisense oligonucleotide
02
Targets
ILF2 (Interleukin enhancer-binding factor 2)
Beyond the preview
Go deeper on ILF2-ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILF2-ASO.